CI
The Cigna Group · Healthcare · Healthcare Plans
Last
$278.64
+$2.27 (+0.82%) 2:15 PM ET
Prev close $276.37
Open $275.98
Day high $279.78
Day low $275.38
Volume 839,673
Avg vol 1,630,407
Mkt cap
$72.87B
P/E ratio
12.55
FY Revenue
$273.85B
EPS
22.20
Gross Margin
8.95%
Sector
Healthcare
AI report sections
CI
The Cigna Group
No AI report section text found yet for this symbol.
Volume vs average
Intraday (cumulative)
+44% (Above avg)
Vol/Avg: 1.44×
RSI
54.30 (Neutral)
Neutral (40–60)
MACD momentum
Intraday
+0.05 (Strong)
MACD: -0.12 Signal: -0.17
Short-Term
+0.90 (Strong)
MACD: 0.41 Signal: -0.49
Long-Term
+0.89 (Strong)
MACD: -1.45 Signal: -2.35
Intraday trend score 75.00

Latest news

CI 12 articles Positive: 4 Neutral: 5 Negative: 3
Neutral The Motley Fool • Jonathan Ponciano
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026

Boone Capital Management liquidated its entire $13.57 million stake in Cogent Biosciences (945,042 shares) in Q4 2026, despite the stock surging 372% over the past year. The fund reallocated capital to earlier-stage biotech opportunities like TYRA, which has gained 40% in 2026, suggesting a strategic shift toward higher-risk, higher-upside clinical-stage investments.

COGT TYRA MDT MIRM biotech portfolio reallocation clinical-stage precision medicine
Sentiment note

Listed as a top holding (8.3% of AUM, $26.55M) in the fund's portfolio.

Neutral GlobeNewswire Inc. • Ushur
Ushur Launches Voice-Guided Experience for Synchronized Voice and Visual Customer Interactions in Regulated Industries

Ushur announced Voice-Guided Experience, a new capability that enables organizations in regulated industries to guide customers through complex workflows using synchronized voice and mobile interactions. The AI-powered feature keeps voice conversations active while opening a synchronized mobile experience, allowing customers to speak or tap without switching channels. The platform supports 74 languages, maintains enterprise-grade compliance (HITRUST r2, SOC 2, HIPAA), and is designed to improve completion rates and reduce operational burden for healthcare, insurance, and financial services organizations.

CI AFL UNM UNMA AI agents voice-guided experience omnichannel customer service regulated industries
Sentiment note

Cigna is mentioned as a customer relying on Ushur's platform, but the article provides no specific information about Cigna's performance, strategy, or outcomes related to this technology adoption.

Positive GlobeNewswire Inc. • Researchandmarkets.Com
Dental Insurance Global Market Forecast 2026-2032: Plan Types, Customer Types, Distribution Channels, Coverage Levels, Regions, Technologies

The global dental insurance market is projected to grow from USD 118.77 billion in 2026 to USD 198.31 billion by 2032, with a CAGR of 8.72%. Growth is driven by digital transformation, evolving care models, and regulatory shifts. Key trends include provider consolidation, value-based care models, and increased investment in analytics and digital-first distribution channels.

CI UNH HUM MET dental insurance market forecast digital transformation value-based care
Sentiment note

As a major dental insurance provider, Cigna stands to benefit from market growth to USD 198.31 billion by 2032 and can leverage digital platforms and analytics investments for competitive advantage.

Positive Investing.com • Timothy Fries
Cummins Revenue Holds Up as Charges Weigh on Near-Term Earnings Clarity

In recent earnings releases, KKR reported strong revenue of $5.74B (beating $2.11B expectations) but missed on EPS at $1.12 vs $1.14 expected. Cummins exceeded revenue expectations at $8.5B but fell short on EPS at $4.27 vs $5.01 expected due to Electrolyzer business charges. The Cigna Group outperformed on both metrics with $72.47B revenue and $8.08 EPS, demonstrating strong operational discipline.

KKR KKRS KKRT KKRPD earnings revenue EPS fourth quarter 2025
Sentiment note

Strong financial performance with both revenue ($72.47B) and EPS ($8.08) exceeding expectations. Total 2025 revenues increased 11% year-over-year, adjusted operating income reached $8.0B, and company increased quarterly dividend, demonstrating operational discipline and positive outlook.

Positive Benzinga • Vandana Singh
FTC Settlement With Cigna's Pharmacy Benefit Manager Promises Cheaper Insulin, Boosts Dividend On Strong Quarterly Earnings

The FTC finalized a settlement with Cigna's Express Scripts pharmacy benefit manager to reduce anticompetitive practices and lower insulin costs by up to $7 billion over the next decade. Cigna reported strong Q4 2025 earnings, beating revenue and EPS estimates, and increased its quarterly dividend to $1.56 per share. The stock rose 3.53% following the announcement.

CI CVS UNH FTC settlement pharmacy benefit manager insulin costs anticompetitive practices quarterly earnings
Sentiment note

Strong Q4 earnings beat (revenue $72.49B vs $69.83B estimate; EPS $8.08 vs $7.88 estimate), 10% YoY revenue growth, 16% increase in operating income, dividend increase to $1.56/share, and stock up 3.53%. FTC settlement provides regulatory clarity and positions the company favorably for future operations.

Negative GlobeNewswire Inc. • National Community Pharmacists Association
Boom! FTC Squeezes Concessions from Cigna’s Express Scripts

The FTC has secured a landmark settlement with Cigna's Express Scripts requiring elimination of spread pricing, decoupling rebates from drug list prices, relocating its GPO from Switzerland to the U.S., and adopting a cost-plus reimbursement model for independent pharmacies starting in 2027. The NCPA views this as a major victory against anticompetitive PBM practices that have artificially inflated drug prices and harmed independent pharmacies.

CI PBM reform FTC settlement drug pricing spread pricing rebates independent pharmacies pharmacy reimbursement
Sentiment note

Cigna and its Express Scripts subsidiary face significant regulatory penalties including elimination of spread pricing, decoupling of rebates from list prices, relocation of its GPO, and mandatory cost-plus reimbursement model adoption. These concessions represent substantial business practice restrictions and 10 years of FTC monitoring, indicating regulatory pressure and potential financial impact.

Negative Benzinga • Vandana Singh
FTC Delays Drug Middlemen Case While Talks Move Forward

The FTC has paused its administrative case against major pharmacy benefit managers (PBMs) including Cigna, CVS Health, and UnitedHealth Group, suggesting settlement negotiations may be underway. The 14-day suspension delays the evidentiary hearing to July 1. The case, filed in September 2024, accuses PBMs of unfair practices that inflated insulin prices. Recent investigations and political pressure from the Trump administration have intensified scrutiny on PBM practices, particularly regarding markups on specialty drugs and alleged use of shell companies to obscure profits.

CI CVS UNH FTC pharmacy benefit managers settlement negotiations drug pricing insulin prices
Sentiment note

Company is a defendant in the FTC case alleging unfair pricing practices and is under investigation for using shell companies to obscure profits. The case pause suggests potential settlement negotiations, which could result in penalties or operational changes.

Neutral Benzinga • Vandana Singh
UnitedHealth CEO Says Hospitals, Drug Prices Drive US Health Care Costs, Pledges ACA Rebates

UnitedHealth Group CEO Stephen Hemsley testified before House panels that rising hospital prices, consolidation, and prescription drug costs—not insurers—are the primary drivers of U.S. health care spending. He pledged to voluntarily eliminate and rebate profits on ACA exchange coverage this year and urged policy reforms including site-neutral payments and patent reform. UnitedHealth also announced a pilot program to accelerate Medicare Advantage payments for rural hospitals.

UNH CI CVS ELV health insurance ACA rebates Medicare Advantage hospital prices
Sentiment note

Mentioned as appearing before House panels alongside other insurers but no specific company actions or statements reported in the article.

Negative Benzinga • Erica Kollmann
Are CVS, UnitedHealth, Cigna Hiding Billions In PBM Rebates? New Report Claims They Are

A new report from Hunterbrook Media alleges that CVS Health, UnitedHealth Group, and Cigna are using shell subsidiary companies called GPOs (Group Purchasing Organizations) to hide billions of dollars in drug rebates that should be passed to patients. The report claims these companies collect massive fees through their GPOs while telling customers they've passed on 100% of rebates, effectively siphoning off drug discounts meant for patients. Hunterbrook visited the GPO headquarters in Ireland, Switzerland, and Minnesota, finding mostly empty offices despite handling tens of billions in revenue.

CVS UNH CI PBM rebates pharmacy benefit managers GPO shell companies drug pricing healthcare fraud allegations
Sentiment note

Implicated in the scheme to hide billions in rebates through GPO subsidiaries, with reports of uncooperative behavior when questioned.

Positive Benzinga • Vandana Singh
Cigna Offers Cleaner Growth Than Other Health Insurers, Says Analyst

BofA Securities highlighted Cigna's strong potential in commercial health insurance, noting its pharmacy benefit management platform and ability to deliver 10-15% annual EPS growth, while also discussing challenges and opportunities in the healthcare insurance market.

CI UNH ALHC CNC health insurance pharmacy benefits Medicare Medicaid
Sentiment note

Offers clean exposure to commercial health insurance, positioned for 10-15% EPS growth, trades at attractive valuation, and has less government exposure compared to peers

Neutral The Motley Fool • Patrick Sanders
Meet the 2.5% Yield Dividend Stock That Could Soar in 2026

UnitedHealth Group's stock has dropped 35% in 2025 due to misjudged medical service costs, but the company plans to improve profit margins in 2026-2027 by adjusting Medicare Advantage bids and negotiating better rates.

UNH CVS CI healthcare dividend Medicare stock performance profit margins
Sentiment note

Mentioned as a market competitor with no detailed performance discussion

Neutral Benzinga • Vandana Singh
White House Set To Unveil Framework To Extend Obamacare Subsidies

The White House is preparing to introduce a healthcare framework to extend Affordable Care Act subsidies, proposing a two-year extension with updated eligibility limits and measures to control premium increases affecting approximately 22 million Americans.

OSCR CI CNC ELV Obamacare healthcare subsidies insurance costs ACA
Sentiment note

Potential regulatory changes might affect insurance market conditions

News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal